Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.31% | 99.11% | 99.50% | 321.82% | -8.47% |
| Total Depreciation and Amortization | 35.65% | 2.01% | -28.11% | -52.67% | -44.80% |
| Total Amortization of Deferred Charges | -87.37% | -96.14% | 34.91% | -68.26% | 347.75% |
| Total Other Non-Cash Items | 38.84% | -26.68% | -64.42% | 384.76% | 1,212.36% |
| Change in Net Operating Assets | -579.67% | -1,732.66% | -37.78% | -748.11% | 65.05% |
| Cash from Operations | -135.64% | 290.74% | 204.91% | 215.05% | 111.58% |
| Capital Expenditure | -146.23% | -1,492.71% | -284.60% | -122.27% | 46.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -146.23% | -8,716.16% | -284.60% | -122.27% | 46.45% |
| Total Debt Issued | -- | 1,312.17% | -- | -- | -- |
| Total Debt Repaid | -86.96% | -1,846,940.91% | -81.82% | -85.71% | 26.67% |
| Issuance of Common Stock | 2,019.29% | -99.31% | -35.84% | 1,319.85% | 134,670.74% |
| Repurchase of Common Stock | 38.91% | -1,505.85% | -154.55% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -125.57% | -- | 100.00% | 980.08% |
| Cash from Financing | 167.47% | -105.42% | -35.88% | 1,403.98% | 528,318.60% |
| Foreign Exchange rate Adjustments | -280.65% | -129.03% | -350.00% | -2,800.00% | 675.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -174.63% | -119.01% | 171.32% | 205.06% | 1,147.37% |